Patents by Inventor Chunning YANG

Chunning YANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EGFR-CMET-TARGETED COMPOUNDS AND USES THEREOF
    Publication number: 20250121104
    Abstract: Compounds, e.g., radioimmunoconjugates, including a chelating moiety or a metal complex thereof, a linker, and an antibody or antigen-binding fragment thereof targeting both EGFR and cMET. Pharmaceutical compositions of such compounds and methods of treatment for conditions, e.g., cancer, using such compounds or pharmaceutical compositions.
    Type: Application
    Filed: December 20, 2022
    Publication date: April 17, 2025
    Inventors: Sadaf AGHEVLIAN, Natalie GRINSHTEIN, Ian R. DUFFY, Thomas I. KOSTELINK, Andrew Grier BUCHANAN, Yariv MAZOR, Srinath KASTURIRANGAN, Qun DU, Chunning YANG, Frank Irvine COMER
  • STEAP2 DIRECTED T-CELL ENGAGERS AND COMPOSITIONS THEREOF
    Publication number: 20250059295
    Abstract: Provided are T ell engaging molecules that bind an antigen on a non-immune cell and an antigen on an immune cell. The T cell engaging molecules can bind STEAP2 on a cancer cell and, e.g., a CD3 on a T cell. The T cell engaging molecules can also bind STEAP2 on a cancer cell and, e.g., a CD8 on a T cell. Alternatively, the T cell engaging molecules can bind STEAP2 on a cancer cell and both CD3 and CD8 on a T cell.
    Type: Application
    Filed: April 10, 2024
    Publication date: February 20, 2025
    Inventors: Zachary BRITTON, Sao Fong CHEUNG, Jeong Min HAN, Yariv MAZOR, Suzanne SITNIKOVA, Dewald van DYK, Even WALSENG, Chunning YANG, Simon DOVEDI, Saso CEMERSKI, Natalie BURROWS, Nikolaos IOANNOU, Oisin HUHN
  • Optimized CD3 Antigen Binding Domains
    Publication number: 20250019438
    Abstract: The present disclosure relates to antibodies or fragments thereof comprising an antigen binding domain capable of binding to a CD3 protein or a fragment thereof. The present disclosure also relates to such antibodies that bind to CD3 having optimized affinity to induce T cell activation, but without being associated with excessive cytokine release and reduced tolerability. The disclosure also relates to methods of producing these antibodies and their therapeutic uses.
    Type: Application
    Filed: April 9, 2024
    Publication date: January 16, 2025
    Inventors: Yariv MAZOR, Zachary BRITTON, Xiuling LI, Sterling PAYNE, Even WALSENG, Chunning YANG
  • Engineered Antibodies
    Publication number: 20250011426
    Abstract: Provided herein are multispecific antibodies containing a lambda charge pair introduced into the interface of a heavy chain and a light chain to reduce chain mispairing.
    Type: Application
    Filed: April 5, 2024
    Publication date: January 9, 2025
    Inventors: Yariv MAZOR, Vaheh OGANESYAN, Chi-I CHIANG, John David BAGERT, Xiuling LI, Sterling PAYNE, Even WALSENG, Ying FU, Chunlei WANG, Chunning YANG
  • Bispecific Engineered Antibodies
    Publication number: 20240417467
    Abstract: Provided herein is a multispecific antibody containing two antigen binding arms capable of binding to a first target and at least one antigen binding arm capable of binding to a second target. The multispecific antibody includes a lambda charge pair introduced into the interface of a heavy chain and a light chain to reduce chain mispairing.
    Type: Application
    Filed: April 6, 2024
    Publication date: December 19, 2024
    Inventors: Yariv MAZOR, Vaheh OGANESYAN, Chi-I CHIANG, John David BAGERT, Xiuling LI, Sterling PAYNE, Even WALSENG, Ying FU, Chunlei WANG, Chunning YANG
  • Trispecific Engineered Antibodies
    Publication number: 20240417468
    Abstract: Provided herein are trispecific antibodies containing three antigen binding arms each capable of binding to a different target, wherein each antigen binding arm contains a different lambda or kappa charge pair introduced into the interface of the respective heavy and light chains to reduce chain mispairing.
    Type: Application
    Filed: April 6, 2024
    Publication date: December 19, 2024
    Inventors: Yariv MAZOR, Vaheh OGANESYAN, Chi-I CHIANG, John David BAGERT, Xiuling LI, Sterling PAYNE, Even WALSENG, Ying FU, Chunlei WANG, Chunning YANG
  • ANTIBODY MOLECULES AND CONJUGATES
    Publication number: 20240360226
    Abstract: The present disclosure relates to antibody molecules that bind epidermal growth factor receptor (EGFR) and/or c-Met and conjugates containing these antibody molecules. The antibody molecules and conjugates find application in the treatment of cancer, for example.
    Type: Application
    Filed: June 25, 2024
    Publication date: October 31, 2024
    Inventors: Frank Irvine COMER, Yariv MAZOR, Srinath KASTURIRANGAN, Qun DU, Chunning YANG, Andrew Grier BUCHANAN
  • Antibody molecules and conjugates
    Patent number: 12065496
    Abstract: The present disclosure relates to antibody molecules that bind epidermal growth factor receptor (EGFR) and/or c-Met and conjugates containing these antibody molecules. The antibody molecules and conjugates find application in the treatment of cancer, for example.
    Type: Grant
    Filed: November 9, 2022
    Date of Patent: August 20, 2024
    Assignee: AstraZeneca AB
    Inventors: Frank Irvine Comer, Yariv Mazor, Srinath Kasturirangan, Qun Du, Chunning Yang, Andrew Grier Buchanan
  • COMPOSITIONS AND METHODS OF TREATING CANCER WITH CHIMERIC ANTIGEN RECEPTORS TARGETING CLAUDIN 18.2
    Publication number: 20240228610
    Abstract: This disclosure relates to compositions and methods for treating cancer using chimeric antigen receptor T cells and/or antigen binding domains targeting CLDN18.2.
    Type: Application
    Filed: October 5, 2023
    Publication date: July 11, 2024
    Inventors: ALLISON MARIE BARRETT, ZACHARY THOMAS BRITTON, SHANNON BREEN, ROSA CARRASCO, CHUNNING YANG, GORDON MOODY, AMANDA HATKE
  • COMPOSITIONS AND METHODS OF TREATING CANCER WITH CHIMERIC ANTIGEN RECEPTORS TARGETING CLAUDIN 18.2
    Publication number: 20240132587
    Abstract: This disclosure relates to compositions and methods for treating cancer using chimeric antigen receptor T cells and/or antigen binding domains targeting CLDN18.2.
    Type: Application
    Filed: October 4, 2023
    Publication date: April 25, 2024
    Inventors: ALLISON MARIE BARRETT, ZACHARY THOMAS BRITTON, SHANNON BREEN, ROSA CARRASCO, CHUNNING YANG, GORDON MOODY, AMANDA HATKE
  • ANTIBODY MOLECULES AND CONJUGATES
    Publication number: 20230183358
    Abstract: The present disclosure relates to antibody molecules that bind epidermal growth factor receptor (EGFR) and/or c-Met and conjugates containing these antibody molecules. The antibody molecules and conjugates find application in the treatment of cancer, for example.
    Type: Application
    Filed: November 9, 2022
    Publication date: June 15, 2023
    Inventors: Frank Irvine COMER, Yariv MAZOR, Srinath KASTURIRANGAN, Qun DU, Chunning YANG, Andrew Grier BUCHANAN
  • BISPECIFIC ANTIBODY TARGETING PD-1 AND TIM-3
    Publication number: 20220332818
    Abstract: The present disclosure provides methods of altering engagement between T-cell immunoglobulin and mucin domain containing protein-3 (TIM-3) and phosphatidylserine (PS) in a subject. Also provided are methods of treatment using TIM-3 binding protein wherein the TIM-3 binding domain specifically binds to the C?C? and DE loops of the immunoglobulin variable (IgV) domain of TIM-3.
    Type: Application
    Filed: April 12, 2022
    Publication date: October 20, 2022
    Inventors: Kristen POLLIZZI, Scott A. HAMMOND, Yariv MAZOR, Trinity PERRY, Stacy PRYTS, Ashvin R. JAISWAL, Vaheh OGANSEYAN, Chunning YANG, Raffael KUREK, Natalia CEAICOVSCAIA, Charles FERTE, Eleanor CLANCY-THOMPSON